William Blair Comments on Zevra Therapeutics, Inc.’s Q1 2024 Earnings (NASDAQ:ZVRA)

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Stock analysts at William Blair boosted their Q1 2024 earnings per share (EPS) estimates for shares of Zevra Therapeutics in a research report issued on Tuesday, April 16th. William Blair analyst T. Lugo now forecasts that the company will post earnings of ($0.51) per share for the quarter, up from their previous forecast of ($0.52). William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.65) per share. William Blair also issued estimates for Zevra Therapeutics’ Q3 2024 earnings at ($0.44) EPS, Q4 2024 earnings at ($0.36) EPS, FY2024 earnings at ($1.73) EPS, Q1 2025 earnings at ($0.29) EPS, Q2 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.17) EPS, Q4 2025 earnings at ($0.10) EPS and FY2025 earnings at ($0.77) EPS.

A number of other equities research analysts have also issued reports on ZVRA. HC Wainwright restated a “buy” rating and issued a $15.00 price target on shares of Zevra Therapeutics in a research report on Wednesday, April 3rd. Cantor Fitzgerald restated an “overweight” rating on shares of Zevra Therapeutics in a research report on Monday, April 1st. Finally, Maxim Group upped their price target on Zevra Therapeutics from $12.00 to $18.00 and gave the company a “buy” rating in a research report on Tuesday, April 2nd. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Zevra Therapeutics has a consensus rating of “Buy” and an average price target of $19.50.

Zevra Therapeutics Price Performance

NASDAQ:ZVRA opened at $4.50 on Thursday. Zevra Therapeutics has a 12 month low of $3.89 and a 12 month high of $7.28. The stock has a 50 day moving average of $5.89 and a two-hundred day moving average of $5.36. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 0.08. The firm has a market cap of $195.44 million, a P/E ratio of -3.49 and a beta of 1.81.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Nantahala Capital Management LLC raised its stake in shares of Zevra Therapeutics by 6.3% in the fourth quarter. Nantahala Capital Management LLC now owns 2,453,405 shares of the company’s stock valued at $16,070,000 after acquiring an additional 145,189 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Zevra Therapeutics by 2.0% in the fourth quarter. Vanguard Group Inc. now owns 1,645,140 shares of the company’s stock valued at $10,776,000 after acquiring an additional 32,639 shares in the last quarter. Janney Montgomery Scott LLC raised its stake in shares of Zevra Therapeutics by 1.3% in the fourth quarter. Janney Montgomery Scott LLC now owns 683,431 shares of the company’s stock valued at $4,476,000 after acquiring an additional 9,062 shares in the last quarter. Retirement Planning Co of New England Inc. acquired a new stake in shares of Zevra Therapeutics in the third quarter valued at $1,674,000. Finally, Northern Trust Corp raised its stake in shares of Zevra Therapeutics by 11.3% in the fourth quarter. Northern Trust Corp now owns 301,066 shares of the company’s stock valued at $1,972,000 after acquiring an additional 30,624 shares in the last quarter. 35.03% of the stock is currently owned by institutional investors and hedge funds.

About Zevra Therapeutics

Zevra Therapeutics, Inc, a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications.